The Food and Drug Administration (FDA) is holding a hybrid public meeting titled “Prescription Drug User Fee Act and Biosimilar User Fee Amendments Hiring and Retention Assessment on 9/24/2025.
Similar Posts
Pharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/13/2025
Short Title (70 char) Pharmcore Inc. dba Hallandale Pharmacy. Fort Lauderdale, FL. 483 issued 06/13/2025
FEI Number 3014480778
Firm Name Pharmcore Inc. dba Hallandale Pharmacy
Record Type 483
State FLDrug Compliance Programs
FDA compliance programs provide guidance and instructions to FDA staff for obtaining information to help fulfill agency plans in the specified program area.Generic Drug Research Collaboration Opportunities
The Office of Generic Drugs implements the GDUFA Regulatory Science Research Program by collaborating through grants or contracts.Yangzhou Yulou Paper Products Co., Ltd. – 710907 – 09/09/2025
CGMP/Finished Pharmaceuticals/AdulteratedFDA and Kratom
Kratom is not lawfully marketed in the U.S. as a drug product, a dietary supplement, or a food additive in conventional food.BlendHouse LLC. Reading, PA. 483 issued 02/17/2023
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 02/17/2023
Short Title (70 char) BlendHouse LLC. Reading, PA. 483 issued 02/17/2023
FEI Number 3015728839
Firm Name BlendHouse LLC
Record Type 483
State PA
Establishment Type Manufacturer